The rationale of using mesenchymal stem cells in patients with COVID‐19 ‐related acute respiratory distress syndrome: What to expect
Human Clinical Article
[키워드] acute respiratory distress
acute respiratory distress syndrome
acute respiratory syndrome
alveolar
alveolar cell
Antiviral
approach
approved
ARDS
Cell
Clinical management
Clinical outcome
clinical trial
clinical trials
clinics
compassionate use
coronavirus
coronavirus disease
COVID‐19
COVID‐19 patients
COVID‐19
Critical
critical appraisal
Cytokine storm
death
demonstrated
develop
disorder
dysfunction
effective
Efficacy
endogenous repair
feature
Health
ICU
immune response
immune system
Immunocompromised
immunomodulation
infections
inflammatory disease
inhibiting
intensive care
lung edema
Lung function
Mesenchymal stem cells
microenvironment
MSC
MSCs
multiorgan failure
outcome
pandemic
Patient
rapid progress
Registered
resulting
SARS‐CoV‐2
stem cell
syndrome
the patient
therapeutic
Therapeutic approach
therapeutic potential
tissue source
Treatment
Trial
trials
type I
was tested
[DOI] 10.1002/sctm.20-0164 PMC 바로가기 [Article Type] Human Clinical Article
[DOI] 10.1002/sctm.20-0164 PMC 바로가기 [Article Type] Human Clinical Article